Publikationen in Zusammenarbeit mit Forschern von Pharmacoeconomics and Outcomes Research Iberia (29)

2024

  1. Incidence of refractory CMV infection with or without antiviral resistance in Spain: A systematic literature review

    Transplantation Reviews, Vol. 38, Núm. 1

  2. The burden of disease and quality of life in patients with acute hepatic porphyria: COPHASE study

    Medicina Clinica, Vol. 162, Núm. 3, pp. 103-111

2023

  1. Selection of Quality Indicators for the Certification of Dermato-Oncology Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 7, pp. 587-605

  2. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883

2022

  1. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83

  2. Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain

    European Journal of Health Economics, Vol. 23, Núm. 3, pp. 551-558

  3. Cribado dirigido del virus de la inmunodeficiencia humana en los servicios de urgencias en España: análisis de las consecuencias epidemiológicas y económicas

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 34, Núm. 1, pp. 21-28

  4. Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain

    PharmacoEconomics - Open, Vol. 6, Núm. 3, pp. 415-424

2018

  1. Análisis de decisión multicriterio en programas de tratamiento de sustitución de opiáceos en trastornos por consumo de opiáceos

    Adicciones: Revista de socidrogalcohol, Vol. 30, Núm. 3, pp. 167-169

2017

  1. Cost-effectiveness and cost-utility analysis of apixaban versus dabigatran and rivaroxaban in the treatment and secondary prevention of venous thromboembolism

    Pharmacoeconomics - Spanish Research Articles, Vol. 14, Núm. 1, pp. 7-18

  2. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: Update based on the clinical evidence in Spain

    BMC Infectious Diseases, Vol. 17, Núm. 1

  3. Estimación del coste de la nutrición parenteral domiciliaria en España

    Nutricion Hospitalaria, Vol. 34, Núm. 2, pp. 271-276

2016

  1. Análisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis actínica en España

    Actas Dermo-Sifiliograficas, Vol. 107, Núm. 6, pp. 498-508

  2. Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain

    Clinical Drug Investigation, Vol. 36, Núm. 6, pp. 479-490

  3. Cost-effectiveness analysis of apixaban compared to low-molecular-weight heparins and Vitamin K antagonists for treatment and secondary prevention of venous thromboembolism

    Farmacia Hospitalaria, Vol. 40, Núm. 3, pp. 187-208

  4. The value of biological therapies in the treatment of rheumatic chronic diseases. A systematic review of its pharmacoeconomic evidence in Spain

    Pharmacoeconomics - Spanish Research Articles, Vol. 13, Núm. 2, pp. 69-89

2015

  1. Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain

    International Journal of COPD, Vol. 10, Núm. 1, pp. 2027-2036

  2. Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis

    Health Economics Review, Vol. 5, Núm. 1

  3. Cost-effectiveness analysis of lanthanum carbonate versus sevelamer hydrochloride in the treatment of hyperphosphatemia in patients with end-stage renal disease in Spain

    Pharmacoeconomics - Spanish Research Articles, Vol. 12, Núm. 1, pp. 11-22

  4. Use of healthcare resources and costs of acute cardioembolic stroke management in the Region of Madrid: The CODICE Study

    Neurologia, Vol. 30, Núm. 9, pp. 536-544